Pulse Biosciences Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pulse Biosciences, Inc. (PLSE) Misses Q3 EPS by 7c
November 9, 2020 5:05 PM ESTPulse Biosciences, Inc. (NASDAQ: PLSE) reported Q3 EPS of ($0.51), $0.07 worse than the analyst estimate of ($0.44).
Recent Highlights
Submitted a 510(k) Premarket Notification application to the U.S. Food and Drug Administration (FDA) for the CellFX® System seeking to obtain initial clearance for a general dermatologic indication. Potential clearance remains on track to be received as early as the first quarter of 2021.Received FDA Investigational Device Exemption (IDE) approval and completed enrollment ahead... More